Alfred E Mann Charities Inc.

Alfred E. Mann Charities operates as a proactive, invitation-only grantmaker that does not accept unsolicited proposals. The foundation was established in 2016 following the death of Alfred E. Mann, the physicist, inventor, and entrepreneur who founded 17 companies and developed breakthrough medical devices including insulin pumps, cochlear implants, cardiac pacemakers, and retinal prostheses. With $331.8 million in assets, the foundation reflects Mann's lifelong mission of prolonging and improving human lives through healthcare innovation. The grantmaking approach concentrates resources on a relatively small number of high-impact institutions, with the top five grantees receiving the majority of annual disbursements. Cedars-Sinai Medical Center is the single largest beneficiary, receiving $5 million in 2023 alone, reflecting a deep institutional partnership that includes the establishment of the Alfred E. Mann Family Foundation Director's Lab and Science Circle at the Board of Governors Regenerative Medicine Institute. The foundation also maintains significant partnerships with City of Hope (cancer-diabetes research), UCLA (stem cell and nanotechnology research), and Children's Hospital Los Angeles. Beyond healthcare, the foundation supports Jewish cultural organizations, major Los Angeles arts institutions (Getty, LA Opera, MOCA, LACMA), and community services including the LA Regional Food Bank. The foundation has zero full-time employees and is managed by a small board led by President Michael Dreyer.

Alfred E. Mann Charities has shown rapid growth in grantmaking, increasing from $3.8 million in 2020 to $11.6 million in 2023, with 2024 charitable disbursements reaching $17.5 million. The foundation made 140 grants in 2023 (31 in the most recent fiscal year per some sources, suggesting variation in reporting periods), with grants ranging from $5,000 to $5,000,000. The median grant is $10,000, but the average of $140,000 reflects heavy concentration in a few large institutional grants. In 2023, 91 of 140 grants (65%) went to California-based organizations, with New York (18 grants) and Washington DC (6 grants) as secondary markets. Revenue in 2024 was $33.7 million against $47.2 million in expenses, indicating the foundation is spending down assets faster than investment returns replenish them. Revenue sources include $24.2 million in other income (71.8%), $6.9 million in dividends (20.6%), and $2.6 million from asset sales (7.6%). The foundation's asset base of $331.8 million grew dramatically from just $2 million in 2014, reflecting the transfer of Alfred Mann's estate. Total historical grantmaking stands at $29.4 million across 210 grants.

Alfred E. Mann Charities operates in the mid-tier of Los Angeles-area healthcare-focused private foundations. Here is a comparison with peer foundations:

Unlike most peer foundations of comparable size, Alfred E. Mann Charities does not accept unsolicited applications, making it more exclusive and relationship-driven. The foundation's healthcare focus, particularly on biomedical research and medical devices, reflects the founder's personal legacy more directly than most peer foundations. Its rapid asset growth from $2M (2014) to $332M (2024) is unusual, representing a single-donor estate transfer rather than decades of accumulated wealth. The foundation's zero-employee model with high executive compensation is distinctive, relying on board-directed grantmaking rather than a professional program staff.

In November 2025, MannKind Corporation, in partnership with Alfred E. Mann Charities and The Diabetes Link, launched the Centennial Al Mann Scholarship to commemorate what would have been Alfred Mann's 100th birthday. The program will distribute $100,000 in scholarship funds to at least 10 young adult students living with diabetes pursuing higher education in life sciences, with up to $10,000 per student paid in annual installments of $2,500. First awards are planned for the 2026 academic year. The foundation continues its major institutional partnerships, with Cedars-Sinai Medical Center remaining the largest single grantee at $5 million. The partnership with City of Hope focuses on accelerating research between cancer and diabetes, as well as pancreatic, liver, and brain cancers. At UCLA, the foundation supports both the Research Acceleration Fund at the Broad Center of Regenerative Medicine and Stem Cell Research and the Technology Development Fund at the California NanoSystems Institute. The foundation's 2024 financials show charitable disbursements of $17.5 million, a significant increase from the $11.6 million distributed in 2023, suggesting an accelerating pace of grantmaking. The foundation also partners with the Simon Wiesenthal Center and Museum of Tolerance on an exhibit focused on antisemitism.

1. Alfred E. Mann Charities does NOT accept unsolicited grant applications. The foundation only makes contributions to preselected charitable organizations, so there is no open application process to follow. 2. To potentially receive funding, organizations should focus on building relationships through institutional channels. The foundation's largest grants go to organizations where it has established named programs (e.g., the Mann Director's Lab at Cedars-Sinai, the Research Acceleration Fund at UCLA), suggesting deep, multi-year partnerships rather than one-time grants. 3. Organizations working in biomedical research, medical devices, diabetes, cancer, or stem cell research in the Los Angeles area are the strongest fit for the foundation's priorities. Healthcare institutions are by far the largest recipients. 4. For the Centennial Al Mann Scholarship specifically (the one open application opportunity), eligible applicants must be young adults living with diabetes pursuing 2- or 4-year life sciences degrees. Check thediabeteslink.org for application details and deadlines in early 2026. 5. Organizations in arts and culture (particularly Jewish cultural organizations and major LA institutions), community food security, and youth services may also receive consideration, though grants in these areas tend to be significantly smaller ($5,000-$50,000 range) compared to healthcare grants ($1M-$5M). Being based in or serving Los Angeles communities is a strong advantage, as 65% of grants are directed to California.